Characterizing Response to PARP Inhibitor Treatment Combinations in Advanced Prostate Cancer

Area of Science:

• Oncology
• Molecular Biology
• Genitourinary Cancers

Background:

• Advanced prostate cancer treatment benefits from combining PARP inhibitors (PARPi) and androgen receptor pathway inhibitors (ARPi).
• The optimal clinical use and precise mechanisms of these drug combinations remain unclear.
• Investigating alternative strategies to enhance PARPi effectiveness is crucial.

Purpose of the Study:

• To clarify the clinical positioning and mechanisms of PARPi and ARPi combinations in prostate cancer.
• To explore the efficacy of ATM inhibition in combination with PARPi.
• To identify strategies for overcoming resistance to ARPi.

Main Methods:

• Assessing cell viability and morphology in response to PARPi and ARPi combinations in castration-resistant and ARPi-resistant prostate cancer models.
• Evaluating the efficacy of an ATM inhibitor (lartesertib) combined with a PARPi.
• Utilizing Western blots and RNA-sequencing to investigate treatment mechanisms.

Main Results:

• PARPi and ARPi combinations demonstrated effectiveness across all tested models, with greatest benefit observed in ARPi-sensitive cells.
• ARPi did not alter homologous recombination repair gene expression but may elevate PARP activity.
• PARP inhibition increased androgen receptor target gene expression and enhanced sensitivity to enzalutamide.
• ATM inhibition significantly boosted PARPi efficacy, outperforming ARPi combinations in ARPi-resistant models.

Conclusions:

• While PARPi and ARPi combinations are effective in ARPi-resistant prostate cancer, they show stronger efficacy in ARPi-sensitive settings.
• PARP inhibition might enhance ARPi sensitivity through increased androgen receptor activity.
• ATM inhibition presents a potential therapeutic advantage over ARPi in combination with PARPi for ARPi-resistant prostate cancer.
• These findings support further development of PARPi for improved prostate cancer patient outcomes.